These findings, along with new subgroup data from the TEPEZZA Phase 4 clinical trial in patients with long disease duration and low Clinical Activity Score (CAS) and an analysis of the impact of TED on QOL, were shared at the 92nd Annual Meeting of the
The FDA-approved dosing schedule for TEPEZZA is one infusion every three weeks for a total of eight IV infusions. An analysis examined whether patients who experience a treatment disruption, defined as a >60-day gap between consecutive infusions, are more likely to need a second course of treatment. Deidentified data of patients prescribed a second course of TEPEZZA after receiving an initial full course were examined for TED-related claims, enrollment for a second course, number of infusions and time between courses. Undisrupted patients (n=4,230) and disrupted patients (n=1,155) were observed for one year after the initial full course of treatment. The majority of treatment disruptions (96%) were related to the short-term TEPEZZA supply disruption that occurred in late 2020 as a result of government-mandated COVID-19 vaccine production orders. Chi-square tests were performed for significance.
The findings revealed that a higher portion of patients who experienced a disruption in their first course of TEPEZZA were prescribed an additional course of treatment compared with those who completed an undisrupted initial course of TEPEZZA (10.5% vs 6.5%; p
(C) 2023 Electronic News Publishing, source